Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Targeting bone metastasis and hypercalcemia

19.11.2002


Most cancer patients are not killed by their primary tumors but succumb to metastatic disease. The most common human cancers--lung, breast, and prostate--frequently spread to bone, causing suffering and morbidity through pain, fractures, and nerve compression syndromes.



Tumor cells enter bones through blood and lymphatic vessels. In order to establish bone metastases, they have to influence bone metabolism. Most breast cancers that spread to bone express high levels of parathyroid hormone related protein, or PTHrP, a molecule that promotes bone breakdown. Scientists believe that the bone breakdown caused by PTHrP starts a vicious cycle: cross-talk between the tumor cells and the osteoclasts, cells that specialize in breaking down bone, ultimately leads to more and more bone loss and more and more aggressive growth of the tumor.

Consistent with this scenario, inhibition of osteoclast activity not only decreases bone lesions but also reduces tumor burden in animals. Preliminary results from human patients treated with bisphosphonates, a group of drugs also used to prevent and treat osteoporosis, suggest that the same might be true in humans.


An article in the November 18 issue of the Journal of Clinical Investigation focuses on direct inhibition of PTHrP, the molecule that is believed to play a critical role in starting the vicious cycle in most breast cancers that metastasize to bone.

Wolfgang Gallwitz and colleagues (of Osteoscreen Ltd in San Antonio, Texas) identified two compounds that inhibit PTHrP production in human breast cancer cells. In animal models, the compounds did reduce metastatic bone breakdown, and compared favorably with bisphoshonates. The mode of action of the two classes of drugs is different--the new compounds inhibit PTHrP production and secretion by the tumor cells whereas bisphosphonates inhibit osteoclasts--which suggests that the two drugs might have synergistic effects when used in combination.

In an accompanying Commentary, T. John Martin, of St. Vincent’s Institute of Medical Research in Melbourne, Australia, discusses the findings in the context of our understanding of bone metabolism and comments on potential therapeutic benefits and risks of PTHrP inhibitors in cancer.

PTHrP secretion by tumor cells frequently causes another complication in cancer patients, namely elevated calcium levels. The excess calcium comes on the one hand from increased breakdown of bone, and on the other from increased retention of calcium by the kidney. Hypercalcemia occurs in an estimated 10-20% of cancer patients and is the most common life-threatening metabolic abnormality associated with neoplastic disease. Mouse studies performed by Gallwitz and colleagues suggest that their PTHrP inhibitors have potential in the treatment of hypercalcemia as well.


CONTACT:
Wolfgang E. Gallwitz
OsteoScreen, Inc.
Suite 201
2040 Babcock Road
San Antonio, TX 78229
USA
Phone 1: 210-614-0770
Fax 1: 210-614-0797
E-mail: gallwitz@osteoscreen.com


ACCOMPANYING COMMENTARY:
Manipulating the environment of cancer cells in bone: a novel therapeutic approach

CONTACT:
T. John Martin
St. Vincent’s Institute of Medical Research
9 Princes Street
Fitzroy, Melbourne, Victoria 3065
AUSTRALIA
PHONE: 61-3-9288-2480
FAX: 61-3-9416-2676

E-mail: j.martin@medicine.unimelb.edu.au




Brooke Grindlinger, PhD | EurekAlert!
Further information:
http://www.jci.org/
http://www.the-jci.org/press/17124.pdf
http://www.the-jci.org/press/11936.pdf

More articles from Health and Medicine:

nachricht Researchers release the brakes on the immune system
18.10.2017 | Rheinische Friedrich-Wilhelms-Universität Bonn

nachricht Norovirus evades immune system by hiding out in rare gut cells
12.10.2017 | University of Pennsylvania School of Medicine

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Neutron star merger directly observed for the first time

University of Maryland researchers contribute to historic detection of gravitational waves and light created by event

On August 17, 2017, at 12:41:04 UTC, scientists made the first direct observation of a merger between two neutron stars--the dense, collapsed cores that remain...

Im Focus: Breaking: the first light from two neutron stars merging

Seven new papers describe the first-ever detection of light from a gravitational wave source. The event, caused by two neutron stars colliding and merging together, was dubbed GW170817 because it sent ripples through space-time that reached Earth on 2017 August 17. Around the world, hundreds of excited astronomers mobilized quickly and were able to observe the event using numerous telescopes, providing a wealth of new data.

Previous detections of gravitational waves have all involved the merger of two black holes, a feat that won the 2017 Nobel Prize in Physics earlier this month....

Im Focus: Smart sensors for efficient processes

Material defects in end products can quickly result in failures in many areas of industry, and have a massive impact on the safe use of their products. This is why, in the field of quality assurance, intelligent, nondestructive sensor systems play a key role. They allow testing components and parts in a rapid and cost-efficient manner without destroying the actual product or changing its surface. Experts from the Fraunhofer IZFP in Saarbrücken will be presenting two exhibits at the Blechexpo in Stuttgart from 7–10 November 2017 that allow fast, reliable, and automated characterization of materials and detection of defects (Hall 5, Booth 5306).

When quality testing uses time-consuming destructive test methods, it can result in enormous costs due to damaging or destroying the products. And given that...

Im Focus: Cold molecules on collision course

Using a new cooling technique MPQ scientists succeed at observing collisions in a dense beam of cold and slow dipolar molecules.

How do chemical reactions proceed at extremely low temperatures? The answer requires the investigation of molecular samples that are cold, dense, and slow at...

Im Focus: Shrinking the proton again!

Scientists from the Max Planck Institute of Quantum Optics, using high precision laser spectroscopy of atomic hydrogen, confirm the surprisingly small value of the proton radius determined from muonic hydrogen.

It was one of the breakthroughs of the year 2010: Laser spectroscopy of muonic hydrogen resulted in a value for the proton charge radius that was significantly...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

ASEAN Member States discuss the future role of renewable energy

17.10.2017 | Event News

World Health Summit 2017: International experts set the course for the future of Global Health

10.10.2017 | Event News

Climate Engineering Conference 2017 Opens in Berlin

10.10.2017 | Event News

 
Latest News

Electrode materials from the microwave oven

19.10.2017 | Materials Sciences

New material for digital memories of the future

19.10.2017 | Materials Sciences

Physics boosts artificial intelligence methods

19.10.2017 | Physics and Astronomy

VideoLinks
B2B-VideoLinks
More VideoLinks >>>